The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of macrophage checkpoint Clever-1 inhibition with bexmarilimab plus azacitidine in myelodysplastic syndrome: Results from the ph1/2 BEXMAB study.
 
Naval Daver
Employment - MD Anderson Cancer Center
Consulting or Advisory Role - Abbvie; Agios; Amgen; Arog; Astellas Pharma; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Genentech; Gilead Sciences; Immunogen; Jazz Pharmaceuticals; Kite, a Gilead company; Novartis; Pfizer; SERVIER; Shattuck Labs; Stemline/Menarini; Syndax; Trillium Therapeutics
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); FATE Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Glycomimetics (Inst); Hanmi (Inst); Immunogen (Inst); Kite, a Gilead company (Inst); Novimmune (Inst); Pfizer (Inst); Servier (Inst); Trillium Therapeutics (Inst); Trovagene (Inst)
 
Mika Kontro
Consulting or Advisory Role - Abbvie; Faron Pharmaceuticals; Ferring; PROTEINA; SERVIER
Speakers' Bureau - Abbvie; Astellas Pharma; SERVIER
 
Johanna Rimpiläinen
Travel, Accommodations, Expenses - Abbvie; Amgen; Pfizer; Sanofi
 
Marja Pyörälä
Consulting or Advisory Role - Abbvie; Amgen; Kuopio Center for Gene and Cell Therapy; SERVIER
Travel, Accommodations, Expenses - Abbvie
 
Timo Siitonen
Consulting or Advisory Role - Abbvie; Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Otsuka
Speakers' Bureau - Abbvie; Janssen-Cilag
Travel, Accommodations, Expenses - Abbvie
 
Mikko Myllymäki
Research Funding - Gilead Sciences
 
Joshua Zeidner
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb/Celgene; Daiichi Sankyo/UCB Japan; Foghorn Therapeutics; Genentech; Genmab; Gilead Sciences; Immunogen; NeoGenomics Laboratories; Novartis; Sellas Life Sciences; SERVIER; Shattuck Labs; Sumitomo Pharma Oncology; Syndax; Takeda
Research Funding - Abbvie (Inst); Akeso Biopharma (Inst); Arog (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Faron Pharmaceuticals (Inst); Gilead Sciences (Inst); Jazz Pharmaceuticals (Inst); Loxo (Inst); Merck (Inst); Newave Pharmaceutical (Inst); Novartis (Inst); Sellas Life Sciences (Inst); Shattuck Labs (Inst); Stemline Therapeutics (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Zentalis (Inst)
 
Ruth Witherall
No Relationships to Disclose
 
Emma Searle
Honoraria - Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; Johnson & Johnson/Janssen; Pfizer; Sanofi; Syndax
Travel, Accommodations, Expenses - Abbvie; BeiGene; Johnson & Johnson/Janssen; Menarini
 
Petri Bono
Employment - Faron Pharmaceuticals
Leadership - Faron Pharmaceuticals
Stock and Other Ownership Interests - Faron Pharmaceuticals; Terveystalo; TILT Biotherapeutics
Consulting or Advisory Role - Faron Pharmaceuticals; Oncorena; TILT Biotherapeutics
 
Dr Birge Berns
Employment - Faron Pharmaceuticals; tranScrip group Ltd
Stock and Other Ownership Interests - Johnson&Johnson
Travel, Accommodations, Expenses - Faron Pharmaceuticals; tranScrip group Ltd
(OPTIONAL) Uncompensated Relationships - Chair of the Policy and Communication Committee of the Faculty of Pharmaceutical Medicine, UK
 
Sofia Aakko
Employment - Faron Pharmaceuticals
 
Maija Hollmen
Employment - Faron Pharmaceuticals
Leadership - Faron Pharmaceuticals
Stock and Other Ownership Interests - Faron Pharmaceuticals; Faron Pharmaceuticals (I)
Research Funding - Faron Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Faron Pharmaceuticals
 
Amer Zeidan
Honoraria - Abbvie; Agios; Akeso Biopharma; ALX Oncology; Amgen; Astellas Pharma; BeiGene; BioCryst; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chiesi; Daiichi Sankyo; Epizyme; Faron Pharmaceuticals; Genentech; Geron; Gilead Sciences; Glycomimetics; Hikma Pharmaceuticals; Janssen; Karyopharm Therapeutics; Keros Therapeutics; Kura Oncology; Kyowa Kirin International; lava therapeutics; Mendus; Notable Labs; Novartis; Orum Therapeutics; Otsuka; Pfizer; Regeneron; Rigel; Schrodinger; SERVIER; Shattuck Labs; Sumitomo Pharma Oncology; Syndax; Syros Pharmaceuticals; Taiho Pharmaceutical; Takeda; Treadwell Therapeutics; Vincerx Pharma; Zentalis
Consulting or Advisory Role - Abbvie; Agios; Akeso Biopharma; ALX Oncology; Amgen; Astellas Pharma; Astex Pharmaceuticals; BeiGene; BioCryst; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chiesi; Daiichi Sankyo; Epizyme; Faron Pharmaceuticals; Genentech; Geron; Gilead Sciences; Glycomimetics; Hikma Pharmaceuticals; Janssen; Karyopharm Therapeutics; Keros Therapeutics; Kura Oncology; Kyowa Kirin International; lava therapeutics; Mendus; Notable Labs; Novartis; Orum Therapeutics; Otsuka; Pfizer; Regeneron; Rigel; Schrodinger; SERVIER; Shattuck Labs; Sumitomo Pharma Oncology; Syndax; Syros Pharmaceuticals; Taiho Pharmaceutical; Takeda; Treadwell Therapeutics; Vincerx Pharma; Zentalis
Research Funding - Abbvie (Inst); Amgen; Astex Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Geron; Kura Oncology; Novartis (Inst); Otsuka; Shattuck Labs; Syros Pharmaceuticals; Takeda (Inst)
 
Anthony Stein
Honoraria - Amgen; Debiopharm Group; Syndex Bio
Consulting or Advisory Role - Debiopharm Group; Sanofi and Daiichi Sankyo; Syndex Bio
Speakers' Bureau - Amgen